SCHEMBL3823767

SCHEMBL3823767

Cc1ccc(S(=O)(=O)N2CCN(C(C)c3nc4ccc(C#N)cc4c(=O)n3C)CC2)cc1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ GPR6 P46095 1/20 0.47
▸ GAA P10253 3/20 0.45
▸ LMNA P02545 1/20 0.45
▸ MAPT P10636 1/20 0.42
▸ KDM4E B2RXH2 3/20 0.41
▸ L3MBTL1 Q9Y468 3/20 0.41
▸ ALDH1A1 P00352 3/20 0.41
▸ HPGD P15428 2/20 0.41
▸ SMN1; SMN2 Q16637 2/20 0.41
▸ MAPK1 P28482 1/20 0.41
▸ TDP1 Q9NUW8 1/20 0.41
▸ CCR6 P51684 1/20 0.40
▸ HSD11B1 P28845 2/20 0.40
▸ GBA1 P04062 1/20 0.40
▸ CFTR P13569 1/20 0.40
▸ METAP1 P53582 1/20 0.39
▸ PKM P14618 2/20 0.39
▸ CACNA2D1 P54289 1/20 0.39
▸ POLB P06746 1/20 0.38
▸ HTT P42858 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15457168 0.93 GBA1 (0.43) GPR6GAALMNAMAPTKDM4E
SCHEMBL3819435 0.92 S1PR1 (0.45) GPR6GAALMNAMAPTL3MBTL1
SCHEMBL3820600 0.90 CFTR (0.46) LMNAKDM4EL3MBTL1ALDH1A1SMN1; SMN2
SCHEMBL3820012 0.87 LMNA (0.48) GAALMNAKDM4EALDH1A1SMN1; SMN2
SCHEMBL3820657 0.86 GAA (0.47) GAALMNAKDM4EALDH1A1HSD11B1
SCHEMBL15457091 0.86 LMNA (0.47) GAALMNAKDM4EALDH1A1SMN1; SMN2
SCHEMBL13724345 0.86 LMNA (0.47) GAALMNAKDM4EALDH1A1SMN1; SMN2
SCHEMBL15457257 0.86 GBA1 (0.52) GAALMNAMAPTKDM4EL3MBTL1
SCHEMBL15457177 0.84 CFTR (0.46) GAALMNAKDM4EALDH1A1SMN1; SMN2
SCHEMBL15457062 0.84 HSD11B1 (0.52) GAALMNAKDM4EALDH1A1HSD11B1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8642609-B2 Modulators of ATP-binding cassette transporters VERTEX PHARMACEUTICALS INCORPORATED (US) 2014-02-04 — — US disclosed
US-8642609-B2 Modulators of ATP-binding cassette transporters VERTEX PHARMACEUTICALS INCORPORATED (US) 2014-02-04 — — US disclosed
US-8642609-B2 Modulators of ATP-binding cassette transporters VERTEX PHARMACEUTICALS INCORPORATED (US) 2014-02-04 — — US disclosed
EP-1646615-B1 PYRIMIDINE DERIVATIVES AS MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS VERTEX PHARMA (US) 2009-08-26 — — EP disclosed
US-20050059687-A1 Modulators of ATP-Binding Cassette transporters VERTEX PHARMACEUTICALS INCORPORATED 2005-03-17 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050059687-A1 Modulators of ATP-Binding Cassette transporters CFTR, ABCB1, ABCC2 GPR6 1065/4885GAA 344/4885LMNA 3024/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback